PAR and the Possible Sales Projection, page-25

It is matter of what price @ what take-up gives what revenue during TGA in 2021 that matters...
Also @Mozzarc
Well the thread started as sales/revenue projections.
I referenced the share price projections of 51C and BellP, and their treatment cycle projections, and then there's yours as well.
My view is that TGA revenue will be critical in setting the end phase III share price.
I don't have any skin in picking the treatment cycle patient price, but would make this point, the price selected will have bearing on the rate of take-up, and that will have a bearing during the TGA revenue period on the corresponding share price, and again as a prelude to the value put on a successful phase III trial outcome. It is on the way. So it is critical to get that right, the pricing as well as everything else.
One option would be for PAR to make TGA pricing an "Introductory Offer with stipulated feedback conditions for WOMAC etc" to justify a price hike in 2022.
Cheers.
I think i will sit back and wait on good news.
Stay safe.